AIM AIM IMMUNOTECH INC revenue, earnings and financials

For the quarter ended June 30, 2026, AIM IMMUNOTECH INC reported revenue of $26.0K (up 4.0% from a year earlier), net income of −$3.79M and diluted EPS of −$0.43; over the last four quarters revenue was $95.0K and net income −$14.3M; for the fiscal year ended December 2025 revenue was $88.0K, down 48.2% on the year before.

AIM annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $88.0K, gross profit n/a, operating income −$11.7M, net income −$14.0M (margin -15861.4%), EPS −$8.62
• Fiscal year ended Dec 2024: revenue $170K, gross profit n/a, operating income −$19.8M, net income −$17.3M (margin -10188.2%), EPS −$30.92
• Fiscal year ended Dec 2023: revenue $202K, gross profit n/a, operating income −$31.9M, net income −$29.0M (margin -14337.6%), EPS −$0.60
• Fiscal year ended Dec 2022: revenue $141K, gross profit n/a, operating income −$19.9M, net income −$19.4M (margin -13790.8%), EPS −$0.40
• Fiscal year ended Dec 2021: revenue $135K, gross profit n/a, operating income −$18.8M, net income −$19.1M (margin -14168.1%), EPS −$0.40

AIM quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $26.0K (up 4.0% year over year), net income −$3.79M, EPS −$0.43
• Quarter ended Mar 31, 2026: revenue $22.0K (up 37.5% year over year), net income −$3.02M, EPS −$0.69
• Quarter ended Dec 31, 2025 (from the annual report): revenue $21.0K (down 53.3% year over year), net income −$4.18M, EPS −$6.46
• Quarter ended Sep 30, 2025: revenue $26.0K (down 25.7% year over year), net income −$3.28M, EPS $1.57
• Quarter ended Jun 30, 2025: revenue $25.0K (down 50.0% year over year), net income −$2.79M, EPS −$3.68
• Quarter ended Mar 31, 2025: revenue $16.0K (down 60.0% year over year), net income −$3.71M, EPS −$0.05
• Quarter ended Dec 31, 2024 (from the annual report): revenue $45.0K (down 30.8% year over year), net income −$5.97M, EPS −$21.80
• Quarter ended Sep 30, 2024: revenue $35.0K (down 23.9% year over year), net income −$3.70M, EPS −$6.00
• Quarter ended Jun 30, 2024: revenue $50.0K (up 19.0% year over year), net income −$1.84M, EPS −$3.00
• Quarter ended Mar 31, 2024: revenue $40.0K (down 18.4% year over year), net income −$5.82M, EPS −$0.12
• Quarter ended Dec 31, 2023 (from the annual report): revenue $65.0K (up 14.0% year over year), net income −$12.6M, EPS −$0.26
• Quarter ended Sep 30, 2023: revenue $46.0K (up 119.0% year over year), net income −$7.82M, EPS −$0.16
• Quarter ended Jun 30, 2023: revenue $42.0K (up 40.0% year over year), net income −$4.91M, EPS −$0.10
• Quarter ended Mar 31, 2023: revenue $49.0K (up 48.5% year over year), net income −$3.66M, EPS −$0.08
• Quarter ended Dec 31, 2022 (from the annual report): revenue $57.0K (up 11.8% year over year), net income −$4.39M, EPS n/a
• Quarter ended Sep 30, 2022: revenue $21.0K (down 36.4% year over year), net income −$6.39M, EPS −$0.13
• Quarter ended Jun 30, 2022: revenue $30.0K (up 30.4% year over year), net income −$4.85M, EPS −$0.10
• Quarter ended Mar 31, 2022: revenue $33.0K (up 17.9% year over year), net income −$3.82M, EPS n/a
• Quarter ended Dec 31, 2021 (from the annual report): revenue $51.0K, net income −$5.85M, EPS −$0.12
• Quarter ended Sep 30, 2021: revenue $33.0K, net income −$3.83M, EPS −$0.08

AIM cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$11.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$14.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$21.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$16.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$14.0M, share buybacks n/a

AIM balance sheet

• Jun 30, 2026: cash $9.90M, total assets $12.7M, total liabilities $4.99M, shareholders' equity $7.74M
• Mar 31, 2026: cash $5.82M, total assets $8.59M, total liabilities $6.46M, shareholders' equity $2.13M, long-term debt $210K
• Dec 31, 2025: cash $2.99M, total assets $5.78M, total liabilities $15.6M, shareholders' equity −$9.78M, long-term debt $927K
• Sep 30, 2025: cash $2.35M, total assets $5.49M, total liabilities $11.6M, shareholders' equity −$6.08M
• Jun 30, 2025: cash $476K, total assets $4.13M, total liabilities $10.7M, shareholders' equity −$6.55M
• Mar 31, 2025: cash $898K, total assets $6.25M, total liabilities $10.1M, shareholders' equity −$3.86M
• Dec 31, 2024: cash $1.70M, total assets $8.61M, total liabilities $9.93M, shareholders' equity −$1.32M
• Sep 30, 2024: cash $915K, total assets $13.6M, total liabilities $10.7M, shareholders' equity $2.91M, long-term debt $139K

What is AIM's revenue?

AIM IMMUNOTECH INC reported $95.0K of revenue over its last four quarters, through June 30, 2026.

Is AIM profitable?

No. AIM IMMUNOTECH INC lost $14.3M over the last four quarters.

What is AIM's EPS?

Diluted earnings per share over the last four quarters were −$6.01; −$0.43 in the latest quarter.

AIM ownership and insider trades · All stocks